ALLAN R BRASIER, MD
Osteopathic Medicine at University Blvd, Galveston, TX
License number
Texas J0922
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
301 University Blvd, Galveston, TX 77555
Phone
(409) 772-2222
Professional information
Director, Sealy Center For Molecular Medicine At Univeristy Of Texas Medical Branch
Position:
Professor and Institute Director at UTMB, Director, Institute for Translational Sciences at University of Texas Medical Branch, Director, NIAID Clinical Proteomics Center at UTMB, Director, Sealy Center for Molecular Medicine at Univeristy of Texas Medical Branch
Location:
Houston, Texas Area
Industry:
Hospital & Health Care
Work:
UTMB
-
Professor and Institute Director
University of Texas Medical Branch
- Galveston, TX since 2008
-
Director, Institute for Translational Sciences
UTMB
since 2008
-
Director, NIAID Clinical Proteomics Center
Univeristy of Texas Medical Branch
- Galveston, TX since Mar 2006
-
Director, Sealy Center for Molecular Medicine
Harvard Medical School
Jul 1987 - Jul 1990
-
Assistant Professor
Education:
University of California, San Francisco - School of Medicine 1979 - 1983
MD, Medicine
MD, Medicine
Skills:
Science
Allan R Brasier, Galveston TX
Specialties:
Endocrinologist
Address:
301 University Blvd, Galveston, TX 77555
Education:
University of California San Francisco, School of Medicine - Doctor of Medicine*
Massachusetts General Hospital - Fellowship - Endocrinology*
Brigham & Women's Hospital - Residency - Internal Medicine*
Massachusetts General Hospital - Fellowship - Endocrinology*
Brigham & Women's Hospital - Residency - Internal Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)*
Dr. Allan R Brasier, Galveston TX - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
UTMB
301 University Blvd, Galveston 77555
(409) 772-2222 (Phone)
301 University Blvd, Galveston 77555
(409) 772-2222 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1989, Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UTMB
301 University Blvd, Galveston 77555
University of Texas Medical Branch Galveston
301 University Blvd, Galveston 77555
301 University Blvd, Galveston 77555
University of Texas Medical Branch Galveston
301 University Blvd, Galveston 77555
Education:
Medical School
University of California At San Francisco
Graduated: 1983
Brigham and Womens Hospital
Massachusetts General Hospital
University of California At San Francisco
Graduated: 1983
Brigham and Womens Hospital
Massachusetts General Hospital
Combinatorial Selection Of Oligonucleotide Aptamers
US Patent:
6423493, Jul 23, 2002
Filed:
Oct 25, 1999
Appl. No.:
09/425798
Inventors:
David G. Gorenstein - Houston TX
David J. King - Galveston TX
Daniel A. Ventura - Galveston TX
Allan R. Brasier - Galveston TX
David J. King - Galveston TX
Daniel A. Ventura - Galveston TX
Allan R. Brasier - Galveston TX
Assignee:
Board of Regents the University of Texas System - Austin TX
International Classification:
C12Q 168
US Classification:
435 6, 435 912, 435 71, 435DIG 47
Abstract:
A random combinatorial selection method is disclosed for the construction of oligonucleotide aptamers in which nuclease resistance is conferred by the inclusion of modified nucleotides. The modified nucleotides are incorporated during PCR amplification to form achiral modified oligonucleotides. Thio-substituted aptamers are provided that bind tightly to the nuclear factor for human IL6 (NF-IL6).
Methods Of Treating Lung Inflammation
US Patent:
6699459, Mar 2, 2004
Filed:
Mar 1, 2002
Appl. No.:
10/087319
Inventors:
Antonella Casola - Galveston TX
Roberto Garofalo - Galveston TX
Allan R. Brasier - Galveston TX
Roberto Garofalo - Galveston TX
Allan R. Brasier - Galveston TX
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A61K 912
US Classification:
424 45, 424 46, 514826, 252397
Abstract:
The present invention relates to a method of treating lung inflammation in a subject which includes administering butylated hydroxyanisol to the subject in an amount effective to treat lung inflammation. The invention also relates to methods of inhibiting interferon regulatory factor activation in a subject and in an alveolar cell. Another aspect of the invention relates to an assay.
Ikk Gamma Gene Products And Methods For Making And Using Same
US Patent:
7521534, Apr 21, 2009
Filed:
Mar 3, 2004
Appl. No.:
10/793339
Inventors:
Allan R. Brasier - Galveston TX, US
Tao Hai - Galveston TX, US
Thomas G. Wood - Houston TX, US
Yuanfen Wei - Galveston TX, US
Tao Hai - Galveston TX, US
Thomas G. Wood - Houston TX, US
Yuanfen Wei - Galveston TX, US
Assignee:
The University Board of Regents of Texas System - Austin TX
International Classification:
C07K 1/00
US Classification:
530350
Abstract:
Disclosed are isolated IKKγΔ; isolated nucleic acid molecules encoding IKKγΔ; expression vectors and cells which contain such nucleic acid molecules; oligonucleotides which are complementary to at least a portion of nucleic acid molecules encoding IKKγΔ but which are not complementary to any portion of nucleic acid molecules encoding wild type IKKγ; antibodies which are specific for IKKγΔ; DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKKγΔ; and DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKKγΔ but which do not hybridize with nucleic acid molecules encoding wild type IKKγ. Methods for using these materials to inhibit formation of IKKγΔ-containing IKK, to inhibit NF-κB activation, and to treat or prevent inflammation are also disclosed.
Single Stranded Dna Aptamers Binding Nf-Kb/Rela
US Patent:
2012026, Oct 18, 2012
Filed:
Apr 12, 2012
Appl. No.:
13/445558
Inventors:
Steven G. Widen - Galveston TX, US
Thomas G. Wood - Houston TX, US
Allan R. Brasier - Galveston TX, US
Yingxin Zhao - Houston TX, US
Thomas G. Wood - Houston TX, US
Allan R. Brasier - Galveston TX, US
Yingxin Zhao - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/7088, G01N 27/62, C12N 5/071, G01N 21/64, G01N 27/72, A61K 49/00, A61P 29/00, A61P 1/00, A61P 11/06, A61P 35/00, A61K 9/127, G01N 33/566, C07H 21/04, B82Y 15/00
US Classification:
424 91, 436501, 435375, 536 231, 514 44 A, 424450, 977774, 977773
Abstract:
DNA aptamers are high affinity ligands selected by genetic enrichment techniques to bind to specific protein targets. Because these represent chemically stable and reproducible molecules, they have application as affinity reagents and/or therapeutic drugs to affect the target protein's actions. NF-kB is an important mediator of the innate immune response and mediator of tissue inflammation. Although RNA and double stranded DNA aptamers have been identified to bind to the NF-kB family of proteins, the present invention represents the first identification of single stranded DNA aptamers that recognize NFkB RelA. The aptamers disclosed herein bind to several distinct regions of RelA and may be useful to antagonize the DNA binding of RelA as an inhibitor of cellular inflammation, visualize the location or amount of RelA in tissues from pathological conditions, or to quantitatively measure the activated state of RelA by affinity binding.
High Affinity Mutants Of Nuclear Factor-Interleukin 6 And Methods Of Use Therefor
US Patent:
5804445, Sep 8, 1998
Filed:
Jan 11, 1996
Appl. No.:
8/585197
Inventors:
Allan R. Brasier - Galveston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07K 14435, C12N 120, C12N 1585
US Classification:
435375
Abstract:
The present invention relates to inhibitors of the sequence specific transcription factor nuclear factor IL-6 (NF-IL6) and methods of use therefor. In particular, substitution mutants in the N-terminus of the NF-IL6 tryptic core domain are disclosed that have a higher binding affinity for the DNA binding site than does the wild-type sequence.
Combinatorial Selection Of Oligonucleotide Aptamers
US Patent:
7179894, Feb 20, 2007
Filed:
Apr 11, 2002
Appl. No.:
10/120815
Inventors:
David G. Gorenstein - Houston TX, US
David J. King - Galveston TX, US
Daniel A. Ventura - Galveston TX, US
Allan R. Brasier - Galveston TX, US
David J. King - Galveston TX, US
Daniel A. Ventura - Galveston TX, US
Allan R. Brasier - Galveston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07H 21/02, C07H 21/04, C12Q 1/68
US Classification:
536 231, 536 245, 435 6
Abstract:
A random combinatorial selection method is disclosed for the construction of oligonucleotide aptamers in which nuclease resistance is conferred by the inclusion of modified nucleotides. The modified nucleotides are incorporated during PCR amplification to form achiral modified oligonucleotides. Thio-substituted aptamers are provided that bind tightly to the nuclear factor for human IL6 (NF-IL6).
Molecular Phenotyping Of Severe Asthma
US Patent:
8053199, Nov 8, 2011
Filed:
Jul 22, 2008
Appl. No.:
12/220263
Inventors:
Allan R. Brasier - Galveston TX, US
William J. Calhoun - League City TX, US
Gary D. Boetticher - Houston TX, US
William J. Calhoun - League City TX, US
Gary D. Boetticher - Houston TX, US
International Classification:
G01N 33/53
US Classification:
435 71, 435 4
Abstract:
The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.